89Strontium in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes
- 1 July 1992
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 66 (1), 177-180
- https://doi.org/10.1038/bjc.1992.238
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Strontium-89 chloride for pain palliation in prostatic skeletal malignancyThe British Journal of Radiology, 1991
- A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to boneEuropean Journal of Cancer and Clinical Oncology, 1991
- Flutamide in Hormone-Resistant Prostatic CancerJournal of Urology, 1990
- Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease.Journal of Clinical Oncology, 1990
- Prostatic Cancer with Bone Metastases: Serum Alkaline Phosphatase (SAP) as a Predictor of Response and the Significance of the SAP “Flare”British Journal of Urology, 1990
- Palliative hemiskeletal irradiation for widespread metastatic prostate cancer: A comparison of single dose and fractionated regimensInternational Journal of Radiation Oncology*Biology*Physics, 1989
- Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.Journal of Clinical Oncology, 1989
- Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone.RadioGraphics, 1989
- Pain experience and pain management among hospitalized cancer patients. A clinical studyCancer, 1989
- Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scanCancer, 1988